Biotech stocks surge on Gilead’s Kite Pharma acquisition – MarketWatch
|
Biotech stocks surge on Gilead's Kite Pharma acquisition
MarketWatch The Kite Pharma acquisition marks a large investment by Gilead into a cancer treatment called chimeric antigen receptor T–cell therapy, or CAR-T, which uses a patient's immune T–cells and re-engineers them to better fight cancer. Juno, Bluebird and … |
